Amikacin

Neonatal sepsis Extended interval dose regimen by slow intravenous injection over 3-5 minutes or by intravenous infusion.

Neonate, 15 mg/kg every 24 hours Multiple daily dose regimen by intramuscular or by slow intravenous injection or by infusion.

Child: 1 month-12 years 7.5 mg/kg every 12 hours, 12-18 years 7.5 mg/kg every 12 hours,

By intravenous injection or infusion. Child: 1 month-18 years initially 15 mg/kg,

Pseudomonal lung infection in cystic fibrosis. Multiple daily dose regimens by slow intravenous injection or infusion.

Brand Name	Manufacturer Name	Distributor	Drug Strength	Packaging	Formulation	Formulation Strength	Price
Amika	Synermed Pharmaceuticals Ltd	Sai Pharmaceuticals Ltd.	100mg	1	Injection	per ml	KES 200.00
Amika	Synermed Pharmaceuticals Ltd	Sai Pharmaceuticals Ltd.	500mg	1	Injection	per ml	KES 275.00
Lanomycin	Pharmathen	Goodman Agencies Ltd	125mg	2ml	Injection	per ampoule	KES 430.00
Lanomycin	Pharmathen	Goodman Agencies Ltd	500mg	2ml	Injection	per ampoule	KES 640.00
Kacin	Aci Limited	Radiance Pharmaceuticals Limited	100mg	10	Injection		KES 1,200.00
Kacin	Aci Limited	Radiance Pharmaceuticals Limited	500mg	10	Injection	per ampoule	KES 2,250.00

Amikacin more info
Mode Of Action	irreversibly binds to 30s sub-unit of bacterial ribosomes; blocks recognition step in protein synthesis and causes growth inhibition.
Drug Indication	Severe infections in hospitalized patients due to susceptible gram-positive bacteria.
Precautions	Neonates, infants and elderly (adjust dose and monitor renal, auditory and vestibular function); avoid prolonged use; conditions characterised by muscular weakness. Peak plasma concentrations of amikacin greater than 30 to 35mcg/mL or trough concentrations greater than 5 to 10mcg/mL should be avoided. Comparisons with equipotent doses found that amikacin affects auditory (cochlear) function to about the same extent as gentamicin.
Contra-Indications	Pregnancy, lactation and myasthenia gravis
Side Effects	Ototoxicity, nephrotoxicity, neuromuscular block and respiratory paralysis, neurotoxicity, vertigo, nausea and vomiting, blood dyscrasia, paraesthesia, skin rash, dry fever, tremor, hypotension, headache.
Dosage	By intramuscular or by slow intravenous injection or by infusion, 15 mg/kg daily in 2 divided doses, increased to 22.5 mg/kg daily in 3 divided doses in severe infections; max. 1.5 g daily for up to 10 days (max. cumulative dose 15 g). Neonatal sepsis Extended interval dose regimen by slow intravenous injection over 3-5 minutes or by intravenous infusion. Neonate, 15 mg/kg every 24 hours Multiple daily dose regimen by intramuscular or by slow intravenous injection or by infusion. Neonate, Loading dose of 10 mg/kg then 7.5 mg/kg every 12 hours Serious Gram-negative infections resistant to gentamicin By slow intravenous injection over 3-5 minutes . Child: 1 month-12 years 7.5 mg/kg every 12 hours, 12-18 years 7.5 mg/kg every 12 hours, increased to 7.5 mg/kg every 8 hours in severe infections, max. 500 mg every 8 hours for up to 10 days (max. cumulative dose 15 g). Once daily dose regimen (not for endocarditis or meningitis). By intravenous injection or infusion. Child: 1 month-18 years initially 15 mg/kg, then adjusted according to serum-amikacin concentration. Pseudomonal lung infection in cystic fibrosis. Multiple daily dose regimens by slow intravenous injection or infusion. Child: 1 month-18 years 10 mg/kg every 8 hours (max. 500 mg every 8 hours)
Pregnancy Category	Category D
Pregnancy Category Description	Drugs, which have caused, are suspected to have caused, or may be expected to cause an increased rise in the frequency of malformations or irreversible damage. These drugs may also have adverse pharmacological effects required required
Drug Category	DRUGS ACTING ON INFECTIONS
Drug Sub-Category	Aminoglycosides